论文信息 - Innovative Therapies to Overcome Resistance to Enzalutamide: Perspective on the Use of Darolutamide. - 字舞流文

Innovative Therapies to Overcome Resistance to Enzalutamide: Perspective on the Use of Darolutamide.

[1] G. Botti,et al. Epithelial-mesenchymal transition in prostate cancer: an overview , 2017, Oncotarget.

[2] Takeshi Yamazaki,et al. Cheminformatics Modeling of Adverse Drug Responses by Clinically Relevant Mutants of Human Androgen Receptor , 2016, J. Chem. Inf. Model..

[3] H. Klocker,et al. Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide , 2016, Oncotarget.

[4] C. Creighton,et al. Androgen deprivation-induced NCoA2 promotes metastatic and castration-resistant prostate cancer. , 2014, The Journal of clinical investigation.

[5] Gang Shao,et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. , 2013, Cancer discovery.

[6] H. Klocker,et al. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. , 2012, The American journal of pathology.

[7] Li Li,et al. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. , 2012, Cancer research.

[8] M. Gleave,et al. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201). , 2018, European urology.